Atherogenic profiles in insulin-dependent diabetic patients and their treatment
- PMID: 1505649
- DOI: 10.1007/BF00145363
Atherogenic profiles in insulin-dependent diabetic patients and their treatment
Abstract
Longitudinal studies have shown a large excess of cardiovascular mortality in insulin-dependent diabetic patients (IDDM) as compared to non-diabetic controls. Although diabetes appears to be an independent cardiovascular risk factor, increases in total and LDL-cholesterol together with a decrease of HDL-cholesterol are more pronounced in diabetics with cardiovascular disease. The general opinion, however, derived from a large number of cross-sectional studies, is that in well-controlled IDDM lipoprotein abnormalities are modest and only slightly different from matched non-diabetic controls. Most of the studies, however, used absolute criteria based on consensus statements and do not take the internal relations of the lipoproteins into account. When atherogenic indices (such as the relationship between total cholesterol and HDL-cholesterol or the Apo A1/apo B quotient) are used, 20 to 30% of an IDDM population considered to be in clinically acceptable control have to be considered pathological. This observation is even more important since the recent Diabetes Control and Complications Trial has shown that, especially in the younger group of patients, significantly higher total cholesterol and triglycerides and lower HDL-cholesterol were observed. Especially in these patients can diet and drug intervention be the most useful in the prevention of cardiovascular disease. These data are consistent with the fact that more sophisticated techniques have previously shown atherogenic changes in the composition of the VLDL-particles and lipoprotein enrichment in apo B. Since these techniques are not easily available in the clinic one has to refer to more classical techniques and the use of above mentioned atherogenic profiles to decide treatment.
Similar articles
-
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.Am J Cardiovasc Drugs. 2005;5(6):379-87. doi: 10.2165/00129784-200505060-00005. Am J Cardiovasc Drugs. 2005. PMID: 16259526 Review.
-
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. doi: 10.1046/j.1462-8902.2003.0310.x. Diabetes Obes Metab. 2003. PMID: 14984018 Review.
-
Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.Metabolism. 1996 Apr;45(4):430-4. doi: 10.1016/s0026-0495(96)90215-2. Metabolism. 1996. PMID: 8609827 Clinical Trial.
-
Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation.Metabolism. 1994 Mar;43(3):333-47. doi: 10.1016/0026-0495(94)90102-3. Metabolism. 1994. PMID: 8139482
-
Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group.Diabetes Care. 1992 Jul;15(7):886-94. doi: 10.2337/diacare.15.7.886. Diabetes Care. 1992. PMID: 1516509 Clinical Trial.
Cited by
-
The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients.J Clin Med. 2021 Jul 21;10(15):3219. doi: 10.3390/jcm10153219. J Clin Med. 2021. PMID: 34362003 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical